GGrantIndex
Sort

326,823 grants matching clinical trial

Center for the Study of Aphasia Recovery (C-STAR)

$2,456,681
Julius Fridriksson · University Of South Carolina At Columbia · P50 · FY2023 · DC

Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit

$2,456,647
Roy M Gulick · Weill Medical Coll Of Cornell Univ · UM1 · FY2014 · AI

Development of a recombinant trimeric RSV-F vaccine (DS-Cav1)

$2,456,526
Frank Arnold · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI

Beta1-selective blockade for prevention of postmenopausal bone loss: A randomized controlled trial

$2,456,365
Sundeep Khosla · Mayo Clinic Rochester · R01 · FY2023 · AG

Translational Research Program in Colorectal Cancer Disparities

$2,455,587
Ulrike Peters · Fred Hutchinson Cancer Center · P50 · FY2025 · CA

NIH StrokeNet National Clinical Coordinating Center (NCC)

$2,455,413
Joseph Paul Broderick · University Of Cincinnati · U01 · FY2025 · NS

Targeted Clincial Trials to Reduce the Risk of Antimocribal Resistance

$2,455,261
Keith Kaye · Wayne State University · N01 · FY2013 · AI

Clinical Evaluation of PET Radiotracers

$2,455,225
Robert Innis · National Institute Of Mental Health · ZIA · FY2022 · MH

University of Pittsburgh Clinical Trials Unit

$2,455,069
John W Mellors · University Of Pittsburgh At Pittsburgh · U01 · FY2011 · AI

B Lymphocyte-Mediated Autoimmunity in Pain After Trauma

$2,454,998
David J Clark · Palo Alto Veterans Instit For Research · R01 · FY2020 · NS

Development of a Next Generation Anthrax Vaccine, dmPA7909

$2,454,564
Sukjoon Park · Emergent Product Development Gaithersbur · U01 · FY2009 · AI

Manufacturing of ABCA1 agonist small molecule peptide CS6253 to support chronic toxicology studies in Wistar rats and Cynomolgus monkeys

$2,454,521
Jan Johansson · Artery Therapeutics, Inc. · R44 · FY2025 · AG

Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders

$2,454,519
Carlos Zarate · National Institute Of Mental Health · ZIA · FY2019 · MH

Alcohol Pharmacokinetics and Pharmacodynamics in Humans

$2,454,429
Vijay Arjun Ramchandani · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2019 · AA

Pelvic floor Disorders Network-Data Coordinating Center

$2,454,210
Catherine A Spino · University Of Michigan At Ann Arbor · U01 · FY2007 · HD

MarkVCID Validation in the General Community

$2,454,154
Ronald C Petersen · Mayo Clinic Rochester · UF1 · FY2021 · NS

NEW APPROACHES TO SURGICAL ONCOLOGY

$2,454,143
Donald L Morton · Saint John'S Cancer Institute · P01 · FY2008 · CA

SPORE in Soft Tissue Sarcoma

$2,453,831
Samuel Singer · Sloan-Kettering Inst Can Research · P50 · FY2025 · CA

Alzheimer's Disease Research Center

$2,453,626
University Of California San Diego · P50 · FY2004 · AG

Development of Novel Vaccine Strategies

$2,453,605
Jeffrey Schlom · Basic Sciences · Z01 · FY2007 · CA

Transforming Human Pancreatic Cancer Into An Immunologic Disease

$2,453,222
Elizabeth Marion Jaffee · Johns Hopkins University · P01 · FY2024 · CA

Long-Acting Parathyroid Hormone Analog for the Treatment of Hypoparathyroidism

$2,453,144
Na Yang · National Center For Advancing Translational Sciences · ZIA · FY2017 · TR

Use of Rapamycin for the Treatment of Hypertrophic Cardiomyopathy in Patients with LEOPARD Syndrome

$2,453,144
Elizabeth Ottinger · National Center For Advancing Translational Sciences · ZIA · FY2017 · TR

A controlled trial of patient centered telepsychiatry interventions

$2,452,907
Peter M Yellowlees · University Of California At Davis · R01 · FY2013 · HS

Clot Lysis: Evaluating Accelerated Resolution of IVH Phase III (CLEAR III)

$2,452,564
Daniel F Hanley · Johns Hopkins University · U01 · FY2013 · NS